STUDI PENGGUNAAN OBAT NEUROPROTEKTAN PADA PASIEN STROKE ISKEMIK (Penelitian Di Rumah Sakit Umum Dr. Saiful Anwar Malang)
DOI:
https://doi.org/10.30595/pji.v10i2.796Abstract
ABSTRAK Stroke adalah sebuah penyakit pada sistem saraf yang disebabkan penyumbatan atau terjadinya luka pada pembuluh darah di otak. Stroke merupakan penyebab kelumpuhan nomor satu di dunia, pembunuh nomor dua di dunia dan merupakan peringkat ketiga penyebab kematian di Amerika Serikat. Stroke iskemik adalah stroke yang paling sering terjadi dengan angka kejadian 88%. Tujuan pengobatan stroke akut adalah menurukan terjadinya kerusakan saraf lebih lanjut dan menurunkan kematian dan kelumpuhan jangka panjang. Neuroprotectan adalah salah satu terapi yang dapat menurunkan kerusakan sel yang mengakibatkan gangguan pembuluh darah untuk mensuplai oksigen. Penelitian bertujuan untuk menentukan pola penggunaan neuroprotectan pada pasien dengan stroke iskemik serta memeriksa hubungan terapi neuroprotectan terkait dosis, rute pemberian, frekuensi pemberian, lama dan waktu pemberian yang dikaitkan dengan data klinik di rumah sakit Dr. Saiful Anwar Malang. Penelitian ini menggunakan pengamatan retrospektif dengan consecutive sampling method pada pasien stroke iskemik dari bulan Oktober 2012 sampai Desember 2012. Pada penelitian ini menunjukkan bahwa 95 pasien (93,14%) menerima citicoline, 2 pasien (4,90%) menerima piracetam, dan 5 pasien (4,90%) menerima kombinasi citicoline dan piracetam. Neuroprotectan yang digunakan secara i.v. dan oral dengan (2x1g)/i.v. citicoline kemudian (2x1g)/p.o sebanyak 27 pasien (26,47%). Penggunaan dosis neuroprotectan, rute pemberian, interval pemberian, dan lama pemberian yang diberikan pada pasien stroke iksemik di rumah sakit Dr. Saiful Anwar sudah sesuai berdasarkan beberapa guidelines yang ada. Kata kunci: neuroprotektan, rumah sakit, stroke iskemik. ABSTRACT Stroke is a neurological disease caused by a blockage or rupture of blood vessels in the brain. Stroke is the number one cause of disability in the world, the second leading killer worldwide and the third leading cause of death in the United States. Ischemic stroke is the most common type of stroke that occurs 88%. The goal of acute stroke treatment are to reduce the ongoing neurologic injury and decrease mortality and long-term disability. Neuroprotectan is one of therapy that intended to reduce the occurrence of cell damage due to impaired blood flow to supply oxygen.The study aims to determine patterns of neuroprotectan utilization in patient with ischemic stroke and to examine the relationship neuroprotectan therapy related to the dose, route of administration, frequency of administration, duration and timing of administration associated with clinical data at the Hospital of Dr. Saiful Anwar Malang. The study is a retrospective observational with consecutive sampling method in ischemic stroke patients from october to december 2012. This study showed there were 95 patients (93.14%) received citicoline, 2 patients (4.90%) received piracetam, and 5 patients (4.90%) received combination of citicoline-piracetam. Neuroprotectan used by i.v and oral administration dominated with (2x1g)/iv citicoline then (2x1g)/p.o as 27 patients (26,47%). The use of neuroprotectan dose, route of administration, interval of administration, and duration of administration that given in ischemic stroke patients in inpatient Dr. Saiful Anwar was appropriate according to some existing guidelines. Key words: neuroprotectan, inpatients, ischemic stroke.References
Aminoff, M.J., Greenberg, D. dan Simon, R.R, 2010. Clinical neurology, sixth edition. USA: McGraw Hill. Hal 285-319.
Bahrudin, M., 2010. Kegawatan neurologi. Batu: Penerbit Cakrawala Indonesia. Hal 103-131.
Budiarto, G., 2002. Stroke and hypertension. Dalam: Pendidikan dokter berkelanjutan, update on neurology. Surabaya : Bagian Ilmu Penyakit Saraf Fakultas Kedokteran Universitas Airlangga/RSUD Dr. Soetomo. Hal 1-19.
Dewanto, G., Suwono, W.J., Riyanto, B., dan Turana, Y., 2009. Diagnosis dan tata laksana penyakit syaraf. Jakarta: Penerbit EGC. Hal 24-31.
Doijad, R.C., Pathan, A.B., Pawar, N.B., Baraskar, S.S., Maske, V.D. dan Gaikwad, S.L., 2012. Therapeutic applications of citicoline and piracetam as fixed dose combination. Journal of Pharma and Bio Science, 2(12):15-20.
Fagan, S.C. dan Hess, D.C., 2008. Stroke. In: Wells, Barbara G., Dipiro, J.T., Schwinghammer, T.L. dan Dipiro, C.V. A Pharmacotherapy: Pathophysiologic Approach, 7th Ed. New York: The McGraw Hills, hal 373-381.
Ginsberg, M.D., 2008. Neuroprotection for ischemic stroke : past, present, and future. NIH Journal, 55(3):363–389.
Junaidi, I. 2011. Stroke: waspadai ancamannya.Yogyakarta: Penerbit Andi. Hal: 71-72, 137-175.
Lisabeth, L., Bushnell, C., 2012. Stroke risk in women: the role of menopause and hormone therapy. Lancet, 11:82-91.
Misbach, J., 2011. Stroke: aspek diagnostik, patofisiologi, manajemen. Jakarta: Balai Penerbit FKUI. Hal: 13-52.
Menku, A., Ogden, M., Saraymen, R., 2010. The protective effects of propofol and citicoline combination in experimental head injury in rats. Turkish Neurosurgery, 20(1):57-62.
Perdossi, 2004. Guideline stroke. Jakarta: Perhimpunan Dokter Spesialis Saraf Indonesia. Hal: 30-33.
Riskesdas, 2007. Laporan Nasional Riskesdas. Jakarta: Badan Penelitian dan Pengembangan Kesehatan Departemen Kesehatan RI. Hal: 110-118.
Strazullo, P., D’elia, L., Bakwin, N., Cappuccio, F.P., 2009. Salt intake, stroke, and cardiovascular disease: metaanalysis of prospective studies. BMJ, 339: 45-67.
Sulistyani, D.O. dan Purhadi, 2013. Analisis terhadap faktor-faktor yang mempengaruhi laju perbaikan kondisi klinis pasien penderita stroke dengan regresi Cox Weibull. Jurnal Sains dan Seni POMITS, 2:2337-3520.
Sweetman, S., 2009. Martindale 36 : The complete drug reference. Britain: Pharmaceautical Press, electronic Version.
Wheble, P.C., Sena, E.S., Macleod, M.R., 2008. A systematic review and meta-analysis of the efficacy of piracetam and piracetam-like compounds in experimental stroke. Cerebrovasc Dis. 25:5–11.
Winblad, B. 2005. Piracetam: a review of pharmacologial properties and clinical uses. CNS Drug Review, 11:169-182.
Winnicka, K., Tomasiak, M., Bielawska, A., 2005. Piracetam: an old drug with novel properties. Drug Research, 62:405-409.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
